Fezakinumab - CISMeF

Preferred Label : Fezakinumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human/Macaca irus/Rattus/Mus musculus Interleukin 22) (Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Lambda-Chain, Dimer; Immunoglobulin G1, Anti-(Human Interleukin 22) (Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Lambda-Chain, Dimer;

NCIt definition : A human monoclonal antibody directed against interleukin-22 (IL-22) with anti-inflammatory activity. Fezakinumab binds to IL-22 and prevents the activity of this interleukin. This leads to an inhibition of inflammation. IL-22, a cytokine and member of the IL-10 superfamily, plays a key role during inflammatory responses.;

UNII : 0S77U25XZ3;

CAS number : 1007106-86-6;

Molecule name : ILV-094;

Détails

Origin ID

C87764;

UMLS CUI

C2981359;

Currated CISMeF NLP mapping
- fezakinumab [MeSH Supplementary Concept]
- fezakinumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- fezakinumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients